

Matthew Sleeman, Senior Director of Biology, Respiratory, Inflammation and Autoimmunity, **MedImmune**

Matt Sleeman is a Senior Director of Biology at the Cambridge site for the Respiratory, Inflammation and Autoimmunity therapeutic area. In this capacity he is responsible for the scientific and operational leadership for a team that provide biological characterisation and target rationale to support the development of novel biologic therapies for the treatment of respiratory and inflammatory diseases, such as chronic obstructive pulmonary disease, asthma, rheumatoid arthritis, Lupus and Idiopathic Pulmonary Fibrosis (IPF). At the Cambridge site the primary focus has been in asthma, COPD, RA and we have a growing focus in lung fibrosis. In addition to delivering the preclinical portfolio we also directly support the ongoing clinical development for molecules such as Tralokinumab an anti-IL13 antibody in asthma & IPF; and Mavrilimumab an Anti-GMCSFR antibody in RA.